Related Experiment Video
Updated: Mar 17, 2026
10:05
Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
Published on: July 7, 2016
9.0K
Cardioprotection by Conditioning Mimetic Drugs
Elpidio Santillo1, Monica Migale, Demetrio Postacchini
1Geriatric Rehabilitative Department of I.N.R.C.A, 63900, Fermo, Italy.
Summary
Drugs that mimic ischemic preconditioning (IP) show promise for protecting the heart. Further research is needed to optimize their use in new cardioprotective strategies.
Area of Science:
- Cardiology
- Pharmacology
- Molecular Biology
Background:
- Ischemic heart disease (IHD) is a leading global cause of death.
- Ischemic preconditioning (IP) is a phenomenon where brief ischemia protects against prolonged insult.
- IP involves molecular pathways activated by signaling substances like adenosine and nitric oxide.
Purpose of the Study:
- To review clinical evidence of drugs that mimic IP.
- To discuss their therapeutic properties and potential clinical applications for cardioprotection.
Main Methods:
- Literature search of Medline and Google Scholar for clinical studies on IP-mimicking drugs.
- Review of English-language research from 1986 to 2016, including clinical trials and reviews.
Main Results:
- Several drugs, including adenosine, nicorandil, and atrial natriuretic peptide, mimic IP effects in clinical trials.
- IP-mimicking drugs have been studied perioperatively for ischemia-reperfusion injury.
- Volatile anesthetic agents also demonstrate cardioprotective effects by inducing IP.
Conclusions:
- IP-mimicking drugs possess significant therapeutic potential for cardioprotection.
- Optimal dosing and timing strategies require further investigation.
- These agents could lead to novel cardioprotective therapies beyond reperfusion.
Related Concept Videos
01:25Cardiopulmonary Resuscitation IV: Pharmacological Management
1.2K
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
1.2K
01:30Cardiomyopathy II: Dilated Cardiomyopathy
725
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
725
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
1.4K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.4K
01:26Heart Failure Drugs: Inotropic Agents
1.8K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.8K
01:18Cardiovascular Drugs: Classification based on Therapeutic Indications
4.5K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
4.5K
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
2.2K
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
2.2K